Supporting people with rare diseases
After 30 years of supporting people with rare diseases, we are formalizing the Sanofi Genzyme access program and will donate at least 100,000 vials of medication for lysosomal storage diseases, a group of rare genetic conditions caused by enzyme deficiencies, every year. That’s enough to treat around 1,000 patients for free in parts of the world where treatment options are limited.
Developing a global access plan
The affordability of our medicines is not the only barrier to access for many people. So too is the speed at which we launch new medicines into the majority of markets. Our goal is to develop a global access plan for all new products, making them available in all chosen markets within two years of launch. This bold ambition will ensure that millions more people receive timely treatment and thousands of lives are saved.
Change the course of malaria
Since 2001, we have pursued a holistic approach to controlling malaria that encompasses the manufacture and supply of medicines as well as a prevention strategy aimed at training healthcare workers to better manage the disease and awareness initiatives to educate the population. In 2050, more than half of the African population will be under 25 years of age, so we have a special focus on reaching children, who can help change the course of malaria for the next generation.